IMPORTANT SAFETY INFORMATION

• Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
• Some individuals with weakened immune systems may have a reduced immune response
• Persons with certain complement deficiencies and persons receiving treatments such as Soliris^® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
• As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N. meningitidis group B infections
• Fainting can occur in association with administration of injectable vaccines, including Trumenba
• The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
• Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
• Tell your health care provider if you are pregnant, or plan to become pregnant
• Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child

INDICATION

• Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
• The effectiveness of the two-dose schedule of Trumenba against diverse N. meningitidis group B strains has not been confirmed